Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment

Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge [Short communication]

(2011) J. van Ingen et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis

(2011) D. A. Williamson et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

(2010) T. Gumbo   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Molecular Detection of Tuberculosis and Rifampin Resistance

(2010) Catharina C. Boehme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs

(2009) S. Goutelle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin

(2009) Anna Zaczek et al.   BMC MICROBIOLOGY

Tuberculosis pharmacotherapy: strategies to optimize patient care

(2009) Carole D Mitnick et al.   EXPERT OPINION ON PHARMACOTHERAPY

Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results

(2009) A. Van Deun et al.   JOURNAL OF CLINICAL MICROBIOLOGY